Background. Yolk sac tumors of the ovary are generally very responsive to c
hemotherapy; however, they are difficult to manage in the setting of platin
um resistance where treatment options are limited and outcomes are poorer.
Case. We present a 39-year-old woman who had a platinum-resistant yolk sac
ovarian tumor. She achieved complete remission on an innovative regimen of
docetaxel, gemcitabine, and thalidomide.
Conclusion. The combination of docetaxel, gemcitabine, and thalidomide migh
t be an active regimen for platinum-resistant ovarian nondysgerminomas and
further investigation of this combination is warranted. (C) 2001 Academic P
ress.